|
Delayed
NSE India S.E.
01:24:14 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 228.30 INR | -1.93% |
|
+17.54% | +33.09% |
| 10-28 | Piramal Pharma Limited, Q2 2027 Earnings Call, Oct 28, 2026 | |
| 10-27 | Piramal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 | CI |
| Market Cap | 309B 3.25B 2.92B 2.7B 2.44B 4.56B 4.62B 32.22B 12.84B 162B 12.19B 11.94B 514B | P/E 2027 * |
191x | P/E 2028 * | 62.5x |
|---|---|---|---|---|---|
| Enterprise Value | 360B 3.78B 3.39B 3.13B 2.84B 5.3B 5.36B 37.45B 14.92B 188B 14.17B 13.87B 597B | EV / Sales 2027 * |
3.42x | EV / Sales 2028 * | 3.01x |
| Free-Float |
45.44% | Yield 2027 * |
0.09% | Yield 2028 * | 0.17% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| PPLPHARMA | Delayed | |
Bombay S.E.
| PPLPHARMA | Delayed |
Last Transcript: Piramal Pharma Limited
| 1 day | -1.55% | ||
| 1 week | +17.54% | ||
| Current month | +10.98% | ||
| 1 month | +9.63% | ||
| 3 months | +17.13% | ||
| 6 months | +43.12% | ||
| Current year | +33.09% |
| 1 week | 185.02 |  | 239.54 |
| 1 month | 185.02 | | 239.54 |
| Current year | 132.3 | | 239.54 |
| 1 year | 132.3 | | 239.54 |
| 3 years | 94.7 | | 307.9 |
| 5 years | 63.1 | | 307.9 |
| 10 years | 63.1 | | 307.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 48 | 2020-03-03 |
Brian Guy
PSD | President | - | 2026-10-18 |
Vivek Valsaraj
DFI | Director of Finance/CFO | 53 | 2020-06-09 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Valsaraj
BRD | Director/Board Member | 53 | 2022-02-08 |
Peter DeYoung
BRD | Director/Board Member | 48 | 2020-03-03 |
| Chairman | 45 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.93% | +17.54% | +12.28% | +140.13% | 3.25B | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,148B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 652B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 505B | |
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 348B | |
| +0.34% | +1.84% | +30.70% | +54.27% | 294B | |
| -0.45% | +1.19% | +2.89% | +26.08% | 264B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 244B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | -0.02% | +1.52% | +37.81% | +82.78% | 404.04B | |
| Weighted average by Cap. | +0.26% | +1.56% | +44.50% | +89.14% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 105B 1.1B 991M 917M 830M 1.55B 1.57B 10.96B 4.36B 55.07B 4.15B 4.06B 175B | 119B 1.25B 1.12B 1.04B 939M 1.75B 1.78B 12.4B 4.94B 62.3B 4.69B 4.59B 198B |
| Net income | 1.7B 17.84M 16M 14.8M 13.4M 25.03M 25.34M 177M 70.46M 889M 66.93M 65.52M 2.82B | 5.18B 54.41M 48.81M 45.13M 40.87M 76.36M 77.28M 540M 215M 2.71B 204M 200M 8.61B |
| Net Debt | 50.2B 527M 473M 437M 396M 740M 749M 5.23B 2.08B 26.27B 1.98B 1.94B 83.39B | 48.81B 512M 460M 425M 385M 719M 728M 5.08B 2.02B 25.54B 1.92B 1.88B 81.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-29 | ₹228.30 | -1.93% | 14,802,813 |
| 26-10-28 | ₹232.80 | +17.15% | 118,072,228 |
| 26-10-27 | ₹198.72 | +1.82% | 2,873,965 |
| 26-10-26 | ₹195.17 | +2.15% | 1,471,129 |
| 26-10-23 | ₹191.07 | -2.01% | 2,465,513 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PPLPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
